Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study
Angiogenesis serves a crucial role in tumor growth. Vascular endothelial growth factor (VEGF) is a potent regulator of tumor angiogenesis and is highly expressed in oral squamous cell carcinoma (OSCC). Bevacizumab, which binds to VEGF-A, inhibits the biological activity of VEGF and is clinically adm...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2018-06, Vol.15 (6), p.8627-8634 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8634 |
|---|---|
| container_issue | 6 |
| container_start_page | 8627 |
| container_title | Oncology letters |
| container_volume | 15 |
| creator | Yoshida, Hisato Yoshimura, Hitoshi Matsuda, Shinpei Ryoke, Takashi Kiyoshima, Tamotsu Kobayashi, Motohiro Sano, Kazuo |
| description | Angiogenesis serves a crucial role in tumor growth. Vascular endothelial growth factor (VEGF) is a potent regulator of tumor angiogenesis and is highly expressed in oral squamous cell carcinoma (OSCC). Bevacizumab, which binds to VEGF-A, inhibits the biological activity of VEGF and is clinically administered by intravenous injection. As intravenous chemotherapy intensifies the side effects experienced by OSCC patients, an alternative treatment option is desirable, particularly for older patients with OSCC who present with systemic disease complications. Generally, local injections of antitumor agents enhance tumoricidal activity and decrease side effects. However, the antitumor effects of peritumoral bevacizumab injections in OSCC are not fully understood. Therefore, the present study examined the effects of peritumoral bevacizumab injections in an experimental nude mouse model of OSCC through immunohistochemical staining for cluster of differentiation (CD)31 and α-smooth muscle actin (α-SMA) and apoptosis assays. It was identified that peritumoral injections of bevacizumab significantly inhibited tumor growth in OSCC xenografts compared with peritumoral saline injections or no treatment (controls), and it was also revealed that treatment with bevacizumab significantly reduced CD31- and α-SMA-positive microvessel density (P |
| doi_str_mv | 10.3892/ol.2018.8399 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5950523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A554530199</galeid><sourcerecordid>A554530199</sourcerecordid><originalsourceid>FETCH-LOGICAL-c576t-35259332f55ba3c9b77eee8d8ece7843866e89b00809a298cba001c87831bc943</originalsourceid><addsrcrecordid>eNptkstu1DAUhiMEolXpjjWyhIS6YAbHjhObBdKoKhepUjewthznZMYjx576UtE-AM-NQ9uhg7AXvn3n2P_xX1Wva7ykXJAP3i4JrvmSUyGeVcd1J8iixpw838-75qg6jXGLS2NtzXn7sjoigmPGRHdc_boYR9ApIj-iHQST8uSDsqiHG6XNXZ5Uj4zbFsR4h9RaGRcT-oPE66wmnyPSYC3SKmjj_KQKjhRyeQA0nwL6Cc6vgxpTWQ9gP6IV2gWwZjJOhVsUUx5uX1UvRmUjnD6MJ9WPzxffz78uLq--fDtfXS4069q0oIwwQSkZGesV1aLvOgDgAwcNHW8ob1vgoseYY6GKSN0rjGvNO07rXouGnlSf7vPucj_BoMGlIkXugpnKW6RXRh6eOLORa38jmWCYEVoSnD0kCP46Q0xyMnEugHJQ1EqCmxYTTEhX0Lf_oFufgyvyCiVYU3S05C-1VhakcaMv9-o5qVwx1jCKayEKtfwPVfoAk9HewWjK_kHAuycBG1A2baK3ef7GeAi-vwd18DEGGPfFqLGcPSa9lbPH5Oyxgr95WsA9_Ogo-hutYMye</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2095433262</pqid></control><display><type>article</type><title>Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Yoshida, Hisato ; Yoshimura, Hitoshi ; Matsuda, Shinpei ; Ryoke, Takashi ; Kiyoshima, Tamotsu ; Kobayashi, Motohiro ; Sano, Kazuo</creator><creatorcontrib>Yoshida, Hisato ; Yoshimura, Hitoshi ; Matsuda, Shinpei ; Ryoke, Takashi ; Kiyoshima, Tamotsu ; Kobayashi, Motohiro ; Sano, Kazuo</creatorcontrib><description>Angiogenesis serves a crucial role in tumor growth. Vascular endothelial growth factor (VEGF) is a potent regulator of tumor angiogenesis and is highly expressed in oral squamous cell carcinoma (OSCC). Bevacizumab, which binds to VEGF-A, inhibits the biological activity of VEGF and is clinically administered by intravenous injection. As intravenous chemotherapy intensifies the side effects experienced by OSCC patients, an alternative treatment option is desirable, particularly for older patients with OSCC who present with systemic disease complications. Generally, local injections of antitumor agents enhance tumoricidal activity and decrease side effects. However, the antitumor effects of peritumoral bevacizumab injections in OSCC are not fully understood. Therefore, the present study examined the effects of peritumoral bevacizumab injections in an experimental nude mouse model of OSCC through immunohistochemical staining for cluster of differentiation (CD)31 and α-smooth muscle actin (α-SMA) and apoptosis assays. It was identified that peritumoral injections of bevacizumab significantly inhibited tumor growth in OSCC xenografts compared with peritumoral saline injections or no treatment (controls), and it was also revealed that treatment with bevacizumab significantly reduced CD31- and α-SMA-positive microvessel density (P<0.01) and increased level of tumor cell apoptosis (P<0.01) compared with the controls. In conclusion, these results collectively support the experimental basis for the clinical development of peritumoral bevacizumab injections for the treatment of OSCC.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2018.8399</identifier><identifier>PMID: 29805597</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Angiogenesis ; Bevacizumab ; Biological activity ; Cancer therapies ; Chemotherapy ; Development and progression ; Drug therapy ; Health aspects ; Immunotherapy ; Lung cancer ; Medical prognosis ; Monoclonal antibodies ; Mouth cancer ; Oral cancer ; Patient outcomes ; Squamous cell carcinoma ; Targeted cancer therapy ; Tumors ; Vascular endothelial growth factor</subject><ispartof>Oncology letters, 2018-06, Vol.15 (6), p.8627-8634</ispartof><rights>COPYRIGHT 2018 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2018</rights><rights>Copyright © 2018, Spandidos Publications 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c576t-35259332f55ba3c9b77eee8d8ece7843866e89b00809a298cba001c87831bc943</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950523/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950523/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29805597$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshida, Hisato</creatorcontrib><creatorcontrib>Yoshimura, Hitoshi</creatorcontrib><creatorcontrib>Matsuda, Shinpei</creatorcontrib><creatorcontrib>Ryoke, Takashi</creatorcontrib><creatorcontrib>Kiyoshima, Tamotsu</creatorcontrib><creatorcontrib>Kobayashi, Motohiro</creatorcontrib><creatorcontrib>Sano, Kazuo</creatorcontrib><title>Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Angiogenesis serves a crucial role in tumor growth. Vascular endothelial growth factor (VEGF) is a potent regulator of tumor angiogenesis and is highly expressed in oral squamous cell carcinoma (OSCC). Bevacizumab, which binds to VEGF-A, inhibits the biological activity of VEGF and is clinically administered by intravenous injection. As intravenous chemotherapy intensifies the side effects experienced by OSCC patients, an alternative treatment option is desirable, particularly for older patients with OSCC who present with systemic disease complications. Generally, local injections of antitumor agents enhance tumoricidal activity and decrease side effects. However, the antitumor effects of peritumoral bevacizumab injections in OSCC are not fully understood. Therefore, the present study examined the effects of peritumoral bevacizumab injections in an experimental nude mouse model of OSCC through immunohistochemical staining for cluster of differentiation (CD)31 and α-smooth muscle actin (α-SMA) and apoptosis assays. It was identified that peritumoral injections of bevacizumab significantly inhibited tumor growth in OSCC xenografts compared with peritumoral saline injections or no treatment (controls), and it was also revealed that treatment with bevacizumab significantly reduced CD31- and α-SMA-positive microvessel density (P<0.01) and increased level of tumor cell apoptosis (P<0.01) compared with the controls. In conclusion, these results collectively support the experimental basis for the clinical development of peritumoral bevacizumab injections for the treatment of OSCC.</description><subject>Angiogenesis</subject><subject>Bevacizumab</subject><subject>Biological activity</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Development and progression</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Medical prognosis</subject><subject>Monoclonal antibodies</subject><subject>Mouth cancer</subject><subject>Oral cancer</subject><subject>Patient outcomes</subject><subject>Squamous cell carcinoma</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkstu1DAUhiMEolXpjjWyhIS6YAbHjhObBdKoKhepUjewthznZMYjx576UtE-AM-NQ9uhg7AXvn3n2P_xX1Wva7ykXJAP3i4JrvmSUyGeVcd1J8iixpw838-75qg6jXGLS2NtzXn7sjoigmPGRHdc_boYR9ApIj-iHQST8uSDsqiHG6XNXZ5Uj4zbFsR4h9RaGRcT-oPE66wmnyPSYC3SKmjj_KQKjhRyeQA0nwL6Cc6vgxpTWQ9gP6IV2gWwZjJOhVsUUx5uX1UvRmUjnD6MJ9WPzxffz78uLq--fDtfXS4069q0oIwwQSkZGesV1aLvOgDgAwcNHW8ob1vgoseYY6GKSN0rjGvNO07rXouGnlSf7vPucj_BoMGlIkXugpnKW6RXRh6eOLORa38jmWCYEVoSnD0kCP46Q0xyMnEugHJQ1EqCmxYTTEhX0Lf_oFufgyvyCiVYU3S05C-1VhakcaMv9-o5qVwx1jCKayEKtfwPVfoAk9HewWjK_kHAuycBG1A2baK3ef7GeAi-vwd18DEGGPfFqLGcPSa9lbPH5Oyxgr95WsA9_Ogo-hutYMye</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Yoshida, Hisato</creator><creator>Yoshimura, Hitoshi</creator><creator>Matsuda, Shinpei</creator><creator>Ryoke, Takashi</creator><creator>Kiyoshima, Tamotsu</creator><creator>Kobayashi, Motohiro</creator><creator>Sano, Kazuo</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180601</creationdate><title>Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study</title><author>Yoshida, Hisato ; Yoshimura, Hitoshi ; Matsuda, Shinpei ; Ryoke, Takashi ; Kiyoshima, Tamotsu ; Kobayashi, Motohiro ; Sano, Kazuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c576t-35259332f55ba3c9b77eee8d8ece7843866e89b00809a298cba001c87831bc943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Angiogenesis</topic><topic>Bevacizumab</topic><topic>Biological activity</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Development and progression</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Medical prognosis</topic><topic>Monoclonal antibodies</topic><topic>Mouth cancer</topic><topic>Oral cancer</topic><topic>Patient outcomes</topic><topic>Squamous cell carcinoma</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>online_resources</toplevel><creatorcontrib>Yoshida, Hisato</creatorcontrib><creatorcontrib>Yoshimura, Hitoshi</creatorcontrib><creatorcontrib>Matsuda, Shinpei</creatorcontrib><creatorcontrib>Ryoke, Takashi</creatorcontrib><creatorcontrib>Kiyoshima, Tamotsu</creatorcontrib><creatorcontrib>Kobayashi, Motohiro</creatorcontrib><creatorcontrib>Sano, Kazuo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshida, Hisato</au><au>Yoshimura, Hitoshi</au><au>Matsuda, Shinpei</au><au>Ryoke, Takashi</au><au>Kiyoshima, Tamotsu</au><au>Kobayashi, Motohiro</au><au>Sano, Kazuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>15</volume><issue>6</issue><spage>8627</spage><epage>8634</epage><pages>8627-8634</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Angiogenesis serves a crucial role in tumor growth. Vascular endothelial growth factor (VEGF) is a potent regulator of tumor angiogenesis and is highly expressed in oral squamous cell carcinoma (OSCC). Bevacizumab, which binds to VEGF-A, inhibits the biological activity of VEGF and is clinically administered by intravenous injection. As intravenous chemotherapy intensifies the side effects experienced by OSCC patients, an alternative treatment option is desirable, particularly for older patients with OSCC who present with systemic disease complications. Generally, local injections of antitumor agents enhance tumoricidal activity and decrease side effects. However, the antitumor effects of peritumoral bevacizumab injections in OSCC are not fully understood. Therefore, the present study examined the effects of peritumoral bevacizumab injections in an experimental nude mouse model of OSCC through immunohistochemical staining for cluster of differentiation (CD)31 and α-smooth muscle actin (α-SMA) and apoptosis assays. It was identified that peritumoral injections of bevacizumab significantly inhibited tumor growth in OSCC xenografts compared with peritumoral saline injections or no treatment (controls), and it was also revealed that treatment with bevacizumab significantly reduced CD31- and α-SMA-positive microvessel density (P<0.01) and increased level of tumor cell apoptosis (P<0.01) compared with the controls. In conclusion, these results collectively support the experimental basis for the clinical development of peritumoral bevacizumab injections for the treatment of OSCC.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>29805597</pmid><doi>10.3892/ol.2018.8399</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2018-06, Vol.15 (6), p.8627-8634 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5950523 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Angiogenesis Bevacizumab Biological activity Cancer therapies Chemotherapy Development and progression Drug therapy Health aspects Immunotherapy Lung cancer Medical prognosis Monoclonal antibodies Mouth cancer Oral cancer Patient outcomes Squamous cell carcinoma Targeted cancer therapy Tumors Vascular endothelial growth factor |
| title | Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T17%3A14%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20peritumoral%20bevacizumab%20injection%20against%20oral%20squamous%20cell%20carcinoma%20in%20a%20nude%20mouse%20xenograft%20model:%20A%20preliminary%20study&rft.jtitle=Oncology%20letters&rft.au=Yoshida,%20Hisato&rft.date=2018-06-01&rft.volume=15&rft.issue=6&rft.spage=8627&rft.epage=8634&rft.pages=8627-8634&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2018.8399&rft_dat=%3Cgale_pubme%3EA554530199%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2095433262&rft_id=info:pmid/29805597&rft_galeid=A554530199&rfr_iscdi=true |